Top in hem/onc: Utomilumab for large B-cell lymphoma; mortality risk in cancer survivors

Data from the ZUMA-11 trial showed that the addition of utomilumab after infusion with axicabtagene ciloleucel may lead to improved outcomes in patients with advanced large B-cell lymphoma.

Researchers reported that the addition of utomilumab (PF-05082566, Pfizer) induced a 75% response rate among patients. It was the top story in hematology/oncology last week.

The second top story covered data that showed mortality due to a second primary cancer was nearly twice as prominent in adolescent and young adult cancer survivors compared with the general population.

Read these and more top stories in hematology/oncology below:

Utomilumab may enhance effectiveness of CAR-T for advanced large B-cell lymphoma

The addition of utomilumab after infusion with axicabtagene ciloleucel (Yescarta, Kite Pharma/Gilead Sciences) induced a 75% response rate among adults with relapsed or refractory large B-cell lymphoma, data from the ZUMA-11 trial showed. Read more.

AYA cancer survivors at higher risk for death due to second primary cancers

Death due to a second primary cancer occurred nearly twice as often among adolescent and young adult cancer survivors compared with the general population, according to study results published in Journal of the National Cancer Institute. Read more.

An adequate amount of life insurance protects income, assets

One of the most important components of a sound financial strategy is to mitigate risk. Read more.

FDA expands Enhertu approval for breast cancer

The FDA expanded the approval of fam-trastuzumab deruxtecan (Enhertu; AstraZeneca, Daiichi Sankyo) to include treatment of patients with HER2-positive metastatic breast cancer who received a prior anti-HER2-based regimen. Read more.

Novartis suspends production of radioligand therapies due to potential quality issues

Novartis temporarily suspended production at two of its radioligand therapy production sites. Read more.